Meeting
2021 Gastrointestinal Cancers Symposium
Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
Authors
Himani Agg
Eli Lilly and Company, Indianapolis, IN
Himani Agg , Yimei Han , Zhanglin Lin Cui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 33)
DOI
10.1200/JCO.2021.39.3_suppl.33
Abstract #
33
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE.
First Author: Hil Hsu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Samuel J Klempner
Poster
2021 ASCO Annual Meeting
Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz